Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Brief Summary: This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record.

The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cladribine Low/Placebo (LLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine High Dose/Placebo (HLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine Low/Low Dose (LLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Cladribine High/Low Dose (HLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/Cladribine Low Dose (PPLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 3.5 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 5.25 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine Low/Low Dose (LLLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine Low/Placebo (LLPP) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine High/Low Dose (HLLL) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Placebo/Cladribine Low Dose (PPLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine High Dose/Placebo (HLPP)
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2

Answer: A